Who we are
Blueprint Genetics is a genetic diagnostics company with operations in San Francisco, Helsinki and Dubai. With a team comprising geneticists, bioinformaticians, DNA biologists, clinical consultants and business developers, we support healthcare professionals around the world in providing the best care for patients with rare inherited diseases. We do that by delivering answers using fast, affordable, and comprehensive genetic diagnostics.
Blueprint Genetics provides genetic knowledge through comprehensive genetic testing services. Our test menu includes over 400 genetic tests covering all medical specialties. We want to provide an easy and fast access to actionable results without ever compromising quality. We take pride in sharing data and being transparent about our sequencing quality and pricing.
Our technologies include OS-Seq, a targeted sequencing technology developed at Stanford and published in Nature. This enables us to provide very high coverage sequencing at a low cost. Our validation report summarizes the strengths of our sequencing quality. In order to provide high quality and up-to-date clinical interpretation of the sequencing results we run a large genetic data platform that is powered by the IBM Watson, we call the platform CLINT.
We are here to bring genetic knowledge into mainstream healthcare, and we believe that cost efficiency without ever compromising quality is key in achieving that.
We provide comprehensive genetic diagnostics to support healthcare professionals around the world in providing the best care for patients with rare inherited diseases. With a conclusive genetic diagnosis, clinicians can start the right course of treatment for their patients, or recommend the necessary lifestyle changes to ensure their patients live as comfortably and as long as possible. The time and expense needed to provide results through traditional genetic testing methods has meant that genetic diagnostics are often used as a last resort. Now, a revolution in genetic testing technology means that patients can get their results in a fraction of the time – and at a fraction of the cost.
What we are looking for
Blueprint genetics is looking to collaborate in the following fields:
• Molecular diagnostics (MDx)
• Next-Generation Sequencing (NGS)
• Storage and management of genetic data
• Clinical interpretation of genetic data
• Rare disorder drug development
Tommi Lehtonen, CEO
Tommi has been running Blueprint Genetics since the beginning and is responsible for sales management, business development, finance and administration. He visits Bay Area frequently and attends life science and diagnostics events regularly. Tommi holds a M.Sc. from the Helsinki University of Technology where he studied business strategy and applied mathematics.
Juha Koskenvuo, Laboratory Director, Chief Medical Officer
Juha is supervising laboratory production and is responsible for designing new diagnostic tests. He participates on a daily basis in clinical evaluation of the genetic findings and further develops variant classification and interpretation practices in the company in collaboration with a team of geneticists.
Samuel Myllykangas, Chief Technology Officer
Samuel is the Head of R&D and Operations at Blueprint Genetics. Samuel is an expert in genome analysis technologies and has wide experience in bioinformatics and cancer genomics research. Samuel did his post-doctoral research in Stanford University, developing high-throughput sequencing technologies. Samuel is a co-founder of Blueprint Genetics.
Tero-Pekka Alastalo, President
Tero-Pekka is the Chief Medical Officer and President of Blueprint Genetics Inc. He is based in San Francisco and in charge of the operations in North America. He is also designing diagnostic panels, mutation databases and works with clinical evaluation of genetic data. During his postdoctoral training, Tero-Pekka focused on the molecular genetic mechanisms of cardiovascular diseases.